ETNK1

Summary

ETNK1 (ethanolamine kinase 1, HGNC:24649) is a protein-coding gene on chromosome 12p12.1, encoding Ethanolamine kinase 1 (Q9HBU6). Highly specific for ethanolamine phosphorylation.

This gene encodes an ethanolamine kinase, which functions in the first committed step of the phosphatidylethanolamine synthesis pathway. This cytosolic enzyme is specific for ethanolamine and exhibits negligible kinase activity on choline. Alternative splicing results in multiple transcript variants encoding distinct isoforms.

Source: NCBI Gene 55500 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 58 total — 1 pathogenic
• MANE Select transcript: NM_018638

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24649
Approved symbol	ETNK1
Name	ethanolamine kinase 1
Location	12p12.1
Locus type	gene with protein product
Status	Approved
Aliases	EKI1, EKI
Ensembl gene	ENSG00000139163
Ensembl biotype	protein_coding
OMIM	609858
Entrez	55500

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 10 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000266517, ENST00000335148, ENST00000538218, ENST00000539974, ENST00000544191, ENST00000545979, ENST00000671733, ENST00000672951, ENST00000672995, ENST00000673188, ENST00000673406, ENST00000673496, ENST00000864020, ENST00000864021, ENST00000930361, ENST00000960838

RefSeq mRNA: 2 — MANE Select: NM_018638 NM_001039481, NM_018638

CCDS: CCDS41760, CCDS8698

Canonical transcript exons

ENST00000266517 — 8 exons

Exon	Start	End
ENSE00001141583	22684882	22690665
ENSE00001177068	22671272	22671355
ENSE00001177071	22661063	22661205
ENSE00001177082	22643763	22644022
ENSE00003483329	22659014	22659154
ENSE00003522583	22684483	22684556
ENSE00003547802	22673500	22673660
ENSE00003895506	22625171	22625586

Expression profiles

Bgee: expression breadth ubiquitous, 281 present calls, max score 98.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 55.1864 / max 4162.5481, expressed in 1820 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
124703	19.2982	1801
124710	13.7301	1535
124704	13.6827	1779
124706	6.2459	1650
124705	1.8307	1183
124708	0.3988	157

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	98.07	gold quality
mucosa of transverse colon	UBERON:0004991	97.23	gold quality
adrenal tissue	UBERON:0018303	97.18	gold quality
bronchial epithelial cell	CL:0002328	96.82	gold quality
pigmented layer of retina	UBERON:0001782	96.44	gold quality
retina	UBERON:0000966	96.41	gold quality
ileal mucosa	UBERON:0000331	96.25	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.14	gold quality
germinal epithelium of ovary	UBERON:0001304	96.06	gold quality
colonic mucosa	UBERON:0000317	95.28	gold quality
mucosa of sigmoid colon	UBERON:0004993	94.76	gold quality
tibia	UBERON:0000979	94.59	gold quality
caput epididymis	UBERON:0004358	94.46	gold quality
epithelium of nasopharynx	UBERON:0001951	94.44	gold quality
corpus epididymis	UBERON:0004359	94.21	gold quality
calcaneal tendon	UBERON:0003701	93.52	gold quality
islet of Langerhans	UBERON:0000006	93.34	gold quality
visceral pleura	UBERON:0002401	93.32	gold quality
duodenum	UBERON:0002114	93.07	gold quality
colonic epithelium	UBERON:0000397	92.86	gold quality
endometrium	UBERON:0001295	92.85	gold quality
stromal cell of endometrium	CL:0002255	92.62	gold quality
rectum	UBERON:0001052	92.51	gold quality
eye	UBERON:0000970	92.40	gold quality
cartilage tissue	UBERON:0002418	92.39	gold quality
cortical plate	UBERON:0005343	92.35	gold quality
superficial temporal artery	UBERON:0001614	92.25	gold quality
ganglionic eminence	UBERON:0004023	92.25	gold quality
parietal pleura	UBERON:0002400	92.10	gold quality
gall bladder	UBERON:0002110	91.94	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	17.40
E-MTAB-8894	no	209.50
E-ENAD-27	no	11.99
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ZNF569

miRNA regulators (miRDB)

392 targeting ETNK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-568	99.98	69.86	2084
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790

Literature-anchored findings (GeneRIF, showing 6)

• DAD-R, SOX5, and EKI1 map within region of chromosome 12p whose duplication is related to reduced apoptosis in human testicular seminomas. (PMID:11912161)
• Recurrent ETNK1 mutations are associated with chronic myeloid leukemia. (PMID:25343957)
• we identified novel somatic missense ETNK1 mutations that were most frequent in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia (PMID:25615281)
• miR-199a-3p regulates the invasion and migration of gastric cancer cells by targeting ETNK1 (PMID:31255331)
• ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine. (PMID:33230096)
• ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. (PMID:36583229)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	etnk1	ENSDARG00000019420
mus_musculus	Etnk1	ENSMUSG00000030275
rattus_norvegicus	Etnk1	ENSRNOG00000014856
drosophila_melanogaster	eas	FBGN0000536
caenorhabditis_elegans		WBGENE00000515

Paralogs (3): CHKB (ENSG00000100288), CHKA (ENSG00000110721), ETNK2 (ENSG00000143845)

Protein

Protein identifiers

Ethanolamine kinase 1 — Q9HBU6 (reviewed: Q9HBU6)

All UniProt accessions (6): Q9HBU6, A0A5F9ZI33, A0A5K1VW28, H0YFP7, H0YH69, Q86U68

UniProt curated annotations — full annotation on UniProt →

Function. Highly specific for ethanolamine phosphorylation. May be a rate-controlling step in phosphatidylethanolamine biosynthesis.

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in kidney, liver, placenta, heart, leukocyte, ovary and testis.

Pathway. Phospholipid metabolism; phosphatidylethanolamine biosynthesis; phosphatidylethanolamine from ethanolamine: step 1/3.

Similarity. Belongs to the choline/ethanolamine kinase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HBU6-1	1	yes
Q9HBU6-2	2

RefSeq proteins (2): NP_001034570, NP_061108* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR011009	Kinase-like_dom_sf	Homologous_superfamily

Pfam: PF01633

Enzyme classification (BRENDA):

• EC 2.7.1.82 — ethanolamine kinase (BRENDA: 27 organisms, 39 substrates, 69 inhibitors, 25 Km, 3 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ETHANOLAMINE	0.008–10	13
ATP	0.0206–10	7
CHOLINE	0.02–0.275	3
DL-1-AMINOPROPAN-2-OL	0.36	1

Catalyzed reactions (Rhea), 1 shown:

• ethanolamine + ATP = phosphoethanolamine + ADP + H(+) (RHEA:13069)

UniProt features (4 total): chain 1, region of interest 1, compositionally biased region 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HBU6-F1	84.76	0.70

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1483213	Synthesis of PE

MSigDB gene sets: 344 (showing top): GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_ORGANOPHOSPHATE_BIOSYNTHETIC_PROCESS, GOBP_PHOSPHOLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, TONKS_TARGETS_OF_RUNX1_RUNX1T1_FUSION_ERYTHROCYTE_UP, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_GLYCEROLIPID_BIOSYNTHETIC_PROCESS, GOBP_GLYCEROPHOSPHOLIPID_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, DOUGLAS_BMI1_TARGETS_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_LIPID_BIOSYNTHETIC_PROCESS, TIEN_INTESTINE_PROBIOTICS_24HR_UP

GO Biological Process (3): phosphatidylethanolamine biosynthetic process (GO:0006646), lipid metabolic process (GO:0006629), phospholipid biosynthetic process (GO:0008654)

GO Molecular Function (6): ethanolamine kinase activity (GO:0004305), ATP binding (GO:0005524), nucleotide binding (GO:0000166), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (3): cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
phosphatidylethanolamine metabolic process	1
glycerophospholipid biosynthetic process	1
primary metabolic process	1
phospholipid metabolic process	1
lipid biosynthetic process	1
organophosphate biosynthetic process	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

1114 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ETNK1	SOX5	P35711	859
ETNK1	SELENOI	Q9C0D9	790
ETNK1	PCYT2	Q99447	747
ETNK1	SETBP1	Q9Y6X0	669
ETNK1	CLPTM1L	Q96KA5	630
ETNK1	PISD	Q9UG56	621
ETNK1	CEPT1	Q9Y6K0	606
ETNK1	DMRT1	Q9Y5R6	601
ETNK1	ZRSR2	Q15696	592
ETNK1	ASXL1	Q8IXJ9	583
ETNK1	CSF3R	Q99062	576
ETNK1	U2AF1	Q01081	570
ETNK1	SRSF2	Q01130	570
ETNK1	SOX6	P35712	548
ETNK1	ATF7IP	Q6VMQ6	548

IntAct

43 interactions, top by confidence:

A	B	Type	Score
NASP	H3C1	psi-mi:“MI:0914”(association)	0.910
ETNK1	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
UBQLN1	ETNK1	psi-mi:“MI:0915”(physical association)	0.560
ETNK1	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
CAMLG	ETNK1	psi-mi:“MI:0915”(physical association)	0.560
SGTB	ETNK1	psi-mi:“MI:0915”(physical association)	0.560
SLC51B	ETNK1	psi-mi:“MI:0915”(physical association)	0.560
SGTA	ETNK1	psi-mi:“MI:0915”(physical association)	0.560
EVA1C	UPK3BL1	psi-mi:“MI:0914”(association)	0.530
PNLIP	LAMC1	psi-mi:“MI:0914”(association)	0.530
PCDHAC2	TMEM223	psi-mi:“MI:0914”(association)	0.530
WDTC1	TCP1	psi-mi:“MI:0914”(association)	0.530
NASP	H4C16	psi-mi:“MI:0914”(association)	0.530
ETNK1	ETNK2	psi-mi:“MI:0915”(physical association)	0.400
SLC18A1	LIMK2	psi-mi:“MI:0914”(association)	0.350
LRRN2	TRIM13	psi-mi:“MI:0914”(association)	0.350
NOCT	NME6	psi-mi:“MI:0914”(association)	0.350
WDTC1	TCP1	psi-mi:“MI:0914”(association)	0.350
NASP	H4C16	psi-mi:“MI:0914”(association)	0.350
NAPRT	ETNK1	psi-mi:“MI:0914”(association)	0.350
ABCA2	ABCD4	psi-mi:“MI:0914”(association)	0.350
GJA10	FBXO42	psi-mi:“MI:0914”(association)	0.350
WDTC1	PHGDH	psi-mi:“MI:0914”(association)	0.350

BioGRID (41): ETNK1 (Two-hybrid), ETNK1 (Co-fractionation), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-MS), ETNK1 (Affinity Capture-RNA), ETNK1 (Two-hybrid), CAMLG (Two-hybrid), SLC51B (Two-hybrid), UBQLN2 (Two-hybrid)

ESM2 similar proteins: A4D126, A4IF87, A4IGD2, A4II32, E0CYC6, E0CYR6, E1BCH6, E9PYK3, E9Q5L8, F1ND48, G1SPE9, O15228, P50747, P79774, P85118, P98192, Q1HAQ0, Q1LWG4, Q3TD49, Q3TFD2, Q3U269, Q4AC99, Q4R8P0, Q5F383, Q5PQL3, Q5RCP1, Q5SZD4, Q8CHQ9, Q8K2I9, Q8NF37, Q8NFZ0, Q90678, Q96GJ1, Q96MI9, Q99487, Q9D1Z3, Q9D4H7, Q9ES71, Q9HBU6, Q9JIY6

Diamond homologs: A7MCT6, A7SK27, D3ZRW8, O54783, O55229, O81024, P54352, Q869T9, Q8L518, Q9D4V0, Q9HBU6, Q9M9H6, Q9NVF9, Q9SZ92, Q9Y259, P20485, O54804, P35790, P46558, P46559, P46560, Q01134, Q22942, P41949, Q554D8

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ETNK1	“up-regulates quantity”	O-phosphonatoethanaminium(1-)	“chemical modification”
ETNK1	“down-regulates quantity”	ethanolaminium(1+)	“chemical modification”

Disease & clinical

Clinical variants and AI predictions

ClinVar

58 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	47
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
666436	GRCh37/hg19 12p12.1(chr12:22602778-25225668)x1	Pathogenic

SpliceAI

1997 predictions. Top by Δscore:

Variant	Effect	Δscore
12:22625572:G:GT	donor_gain	1.0000
12:22643745:A:AG	acceptor_gain	1.0000
12:22643746:A:G	acceptor_gain	1.0000
12:22644018:TTCAG:T	donor_loss	1.0000
12:22644019:TCAG:T	donor_loss	1.0000
12:22644020:CAGG:C	donor_loss	1.0000
12:22644021:AGGT:A	donor_loss	1.0000
12:22644022:GG:G	donor_loss	1.0000
12:22644023:G:T	donor_loss	1.0000
12:22644024:T:G	donor_loss	1.0000
12:22661052:A:AG	acceptor_gain	1.0000
12:22661053:A:G	acceptor_gain	1.0000
12:22661060:AAGGT:A	acceptor_loss	1.0000
12:22671267:C:G	acceptor_gain	1.0000
12:22671268:A:AG	acceptor_gain	1.0000
12:22671268:ATAG:A	acceptor_gain	1.0000
12:22671269:T:G	acceptor_gain	1.0000
12:22671270:A:AG	acceptor_gain	1.0000
12:22671270:A:C	acceptor_loss	1.0000
12:22671271:G:C	acceptor_loss	1.0000
12:22671271:G:GG	acceptor_gain	1.0000
12:22671271:GGT:G	acceptor_gain	1.0000
12:22671351:TGCAG:T	donor_loss	1.0000
12:22671353:CAGG:C	donor_loss	1.0000
12:22671354:AG:A	donor_loss	1.0000
12:22671355:GG:G	donor_loss	1.0000
12:22671356:G:GC	donor_loss	1.0000
12:22671367:G:GT	donor_gain	1.0000
12:22673619:G:GT	donor_gain	1.0000
12:22673658:TTGGT:T	donor_loss	1.0000

AlphaMissense

2414 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:22643776:G:A	G146E	1.000
12:22643782:C:T	T148I	1.000
12:22643784:A:G	N149D	1.000
12:22643785:A:T	N149I	1.000
12:22643786:T:A	N149K	1.000
12:22643786:T:G	N149K	1.000
12:22643791:T:A	L151H	1.000
12:22643791:T:C	L151P	1.000
12:22643830:T:A	V164D	1.000
12:22643833:T:C	L165P	1.000
12:22643839:G:C	R167T	1.000
12:22643840:A:C	R167S	1.000
12:22643840:A:T	R167S	1.000
12:22643848:G:A	G170D	1.000
12:22643848:G:T	G170V	1.000
12:22643943:T:C	F202L	1.000
12:22643945:C:A	F202L	1.000
12:22643945:C:G	F202L	1.000
12:22643952:G:A	G205R	1.000
12:22643952:G:C	G205R	1.000
12:22643953:G:A	G205E	1.000
12:22643953:G:T	G205V	1.000
12:22643958:T:C	C207R	1.000
12:22643959:G:A	C207Y	1.000
12:22643960:C:G	C207W	1.000
12:22643967:T:C	F210L	1.000
12:22643969:T:A	F210L	1.000
12:22643969:T:G	F210L	1.000
12:22643976:G:A	G213R	1.000
12:22643976:G:C	G213R	1.000

dbSNP variants (sampled 300 via entrez): RS1000029850 (12:22646580 T>C), RS1000036930 (12:22623232 C>T), RS1000042073 (12:22651941 C>T), RS1000062438 (12:22666809 A>G), RS1000145776 (12:22646840 A>C), RS1000174821 (12:22676670 A>G), RS1000233800 (12:22629104 A>G), RS1000253754 (12:22648795 C>T), RS1000256957 (12:22686865 T>C), RS1000290479 (12:22640059 C>T), RS1000305938 (12:22649139 C>A,G,T), RS1000315564 (12:22680498 C>A,T), RS1000348578 (12:22635377 C>G), RS1000398153 (12:22633691 C>G,T), RS1000424948 (12:22653677 A>C)

Disease associations

OMIM: gene MIM:609858 | disease phenotypes: MIM:616803

GenCC curated gene-disease

Mondo (2): teratoma (MONDO:0002601), Lamb-Shaffer syndrome (MONDO:0014778)

Orphanet (3): 12p12.1 microdeletion syndrome (Orphanet:313884), Developmental and speech delay due to SOX5 deficiency (Orphanet:313892), Lamb-Shaffer syndrome (Orphanet:530983)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST003817_10	Mortality in sepsis	3.000000e-06
GCST007329_11	Automobile speeding propensity	3.000000e-09
GCST007576_88	Chronotype	5.000000e-10
GCST009182_11	Precuneus cortex volume	8.000000e-06
GCST010002_211	Refractive error	9.000000e-26
GCST010244_375	Triglyceride levels	8.000000e-11

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004352	mortality
EFO:0008579	risk-taking behaviour
EFO:0008328	chronotype measurement
EFO:0004530	triglyceride measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D013724	Teratoma	C04.557.465.910

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

53 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, decreases expression, affects cotreatment	5
methylmercuric chloride	increases expression, affects cotreatment, decreases expression	4
trichostatin A	affects cotreatment, increases expression	3
afimoxifene	decreases response to substance, increases expression	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Rotenone	decreases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
deoxynivalenol	increases expression	1
testosterone undecanoate	affects cotreatment, decreases expression	1
doxifluridine	increases response to substance	1
di-n-butylphosphoric acid	affects expression	1
S 1 (combination)	increases response to substance	1
azoxystrobin	decreases expression	1
CGP 52608	affects binding, increases reaction	1
deguelin	decreases expression	1
monomethylarsonous acid	increases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
thifluzamide	decreases expression	1
abrine	increases expression	1
pyrachlostrobin	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
(+)-JQ1 compound	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1RL	Abcam HeLa ETNK1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

18 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00104676	PHASE3	COMPLETED	Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT00002931	PHASE2	COMPLETED	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
NCT00301782	PHASE2	COMPLETED	Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors
NCT00432094	PHASE2	COMPLETED	Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
NCT00453232	PHASE2	COMPLETED	Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors
NCT00453310	PHASE2	COMPLETED	Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment
NCT00470366	PHASE2	COMPLETED	Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
NCT02300987	PHASE2	COMPLETED	A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
NCT00003643	PHASE2/PHASE3	UNKNOWN	Combination Chemotherapy in Treating Men With Germ Cell Cancer
NCT00423852	PHASE1/PHASE2	COMPLETED	Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
NCT00687778	Not specified	UNKNOWN	11C-Acetate PET/CT Non-FDG-Avid Tumors
NCT00836121	Not specified	COMPLETED	Anterior Mediastinum Teratoma: A Case Report
NCT05179850	Not specified	UNKNOWN	Computer Aided Diagnostic Tool on Computed Tomography Images for Diagnosis of Retroperitoneal Tumor in Children
NCT05187923	Not specified	UNKNOWN	Computer Aided Tool for Diagnosis of Neck Masses in Children
NCT05564026	Not specified	RECRUITING	Molecular Epidemiology of Pediatric Germ Cell Tumors
NCT06421805	Not specified	RECRUITING	Establishing Prospective Mediastinal Tumor Database of PUMCH
NCT07199699	Not specified	NOT_YET_RECRUITING	Subxiphoid VATS for Giant Mediastinal Teratoma